Skip to main content
OpenTrials

Clinical trial condition

Carcinoma, Renal Cell

Explore clinical trials studying Carcinoma, Renal Cell. Study availability and eligibility vary by location and protocol.

154 public trials 10 recruiting studies
Refine in advanced search Browse all conditions

Carcinoma, Renal Cell trial results

Active, not recruiting

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study

NCT05899049

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
Locations
  • Beijing Cancer hospital-Renal carcinoma and melanoma ( Site 6000) Beijing, Beijing Municipality, China
  • Chongqing University Cancer Hospital ( Site 6009) Chongqing, Chongqing Municipality, China
  • SUN YAT-SEN UNIVERSITY CANCER CENTRE ( Site 6003) Guangzhou, Guangdong, China
  • The First Affiliated Hospital of Guangzhou Medical University-Urology ( Site 6036) Guangzhou, Guangdong, China
View all 17 locations
View Trial Details
Active, not recruiting

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

NCT04736706

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
Locations
  • The University of Alabama at Birmingham ( Site 0010) Birmingham, Alabama, United States
  • UC San Diego ( Site 0050) La Jolla, California, United States
  • Cedars Sinai Medical Center ( Site 0027) Los Angeles, California, United States
  • University of California Irvine ( Site 0029) Orange, California, United States
View all 262 locations
View Trial Details
Active, not recruiting

Savolitinib vs. Sunitinib in MET-driven PRCC.

NCT03091192

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +15 more
Locations
  • Research Site La Jolla, California, United States
  • Research Site Atlanta, Georgia, United States
  • Research Site Chicago, Illinois, United States
  • Research Site Iowa City, Iowa, United States
View all 59 locations
View Trial Details
Active, not recruiting

A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)

NCT05239728

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
Locations
  • Mayo Clinic in Arizona - Phoenix ( Site 3554) Phoenix, Arizona, United States
  • City of Hope Comprehensive Cancer Center ( Site 3567) Duarte, California, United States
  • Moores Cancer Center-Clinical Trials Office- Genitourinary ( Site 3516) La Jolla, California, United States
  • UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro ( Site 3520) Los Angeles, California, United States
View all 285 locations
View Trial Details
Active, not recruiting

A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

NCT04195750

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +13 more
Locations
  • Faculty Office Towers 1132 ( Site 1538) Birmingham, Alabama, United States
  • University of California San Diego Moores Cancer Center ( Site 1546) La Jolla, California, United States
  • St. Joseph Heritage Healthcare Local Lab ( Site 1531) Santa Rosa, California, United States
  • University of Colorado Cancer Center ( Site 1540) Aurora, Colorado, United States
View all 172 locations
View Trial Details
Active, not recruiting

A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)

NCT04586231

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +13 more
Locations
  • Ironwood Cancer & Research Centers ( Site 0077) Chandler, Arizona, United States
  • Cedars Sinai Medical Center ( Site 0027) Los Angeles, California, United States
  • UCLA Hematology/Oncology - Santa Monica ( Site 0048) Los Angeles, California, United States
  • St. Joseph Hospital-The Center for Cancer Prevention and Treatment ( Site 0095) Orange, California, United States
View all 184 locations
View Trial Details
Active, not recruiting

A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers

NCT05544929

Conditions
Adenocarcinoma, Adenocarcinoma, Clear Cell, Adenoma, +83 more
Locations
  • Massachusetts General Hospital . Boston, Massachusetts, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • NYU School of Medicine New York, United States
  • University of Pittsburgh Medical Center Pittsburgh, Pennsylvania, United States
View all 19 locations
View Trial Details
Completed

Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)

NCT04626518

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
Locations
  • University of California at San Francisco ( Site 3008) San Francisco, California, United States
  • Yale-New Haven Hospital-Yale Cancer Center ( Site 3011) New Haven, Connecticut, United States
  • University of Chicago ( Site 3013) Chicago, Illinois, United States
  • University of Iowa ( Site 3012) Iowa City, Iowa, United States
View all 51 locations
View Trial Details

Related conditions